Vaccines in the fight against antimicrobial resistance – perspectives from South Africa
DOI:
https://doi.org/10.7196/Keywords:
health care systems, drugs, antimicrobialAbstract
Antimicrobial resistance (AMR), in which microbes adapt to and resist current therapies, is a well-recognised global problem that threatens to reverse gains made by modern medicine in the last decades. AMR is a complex issue; however, at its core, it is driven by the overuse and inappropriate use of antimicrobials. Socioeconomic factors have been identified as significant contributors to the emergence and exacerbation of AMR, especially in populations facing inadequate access to healthcare, poor sanitation services and high morbidity and mortality rates. Weak healthcare systems and water, sanitation and hygiene have been highlighted as fundamental risk factors for AMR emergence and transmission. Behavioural factors, such as purchasing antibiotics without a prescription from a registered healthcare professional, not completing the prescribed course or overly prolonged courses of antibiotics, using antibiotics to treat viral infections, lack of access to quality antibiotics, and the proliferation of substandard or falsified (SF) drugs, have also been identified as significant contributors to AMR. Low- and middle-income countries have a higher incidence of antibiotics being dispensed without a prescription than higher-income countries.
References
Cavany S, Nanyonga S, Hauk C, et al. The uncertain role of substandard and falsified medicines in the emergence and spread of antimicrobial resistance. Nature Commun 2023;14(1):6153. https://doi. org/10.1038/s41467-023-41542-w
Walsh TR, Gales AC, Laxminarayan R, Dodd PC. Antimicrobial resistance: Addressing a global threat to humanity. PLoS Med 2023;20(7):e1004264. https://doi.org/10.1371/journal.pmed.1004264
Li J, Zhou P, Wang J, et al. Worldwide dispensing of non-prescription antibiotics in community pharmacies and associated factors: A mixed-methods systematic review. Lancet Infect Dis 2023;23(9):e361-e370. https://doi.org/10.1016/S1473-3099(23)00130-5
Godman B, Egwuenu A, Wesangula E, et al. Tackling antimicrobial resistance across sub-Saharan Africa: Current challenges and implications for the future. Expert Opin Drug Safety 2022;21(8):1089- 10111. https://doi.org/10.1080/14740338.2022.2106368
Do NT, Vu HT, Nguyen CT, et al. Community-based antibiotic access and use in six low-income and middle-income countries: A mixed-method approach. Lancet Glob Health 2021;9(5):e610-e619. https://doi.org/10.1016/S2214-109X(21)00024-3
One Health Trust. ARVac Consortium Overview. Washington, DC: One Health Trust, n.d. https:// onehealthtrust.org/projects/arvac-consortium/ (accessed 8 January 2024).
Fu H, Lewnard JA, Frost I, Laxminarayan R, Arinaminpathy N. Modelling the global burden of drug- resistant tuberculosis avertable by a postexposure vaccine. Nature Commun 2021;12(1):424. https:// doi.org/10.1038/s41467-020-20731-x
Gates Foundation. Wellcome and the Gates Foundation to fund late-stage development of a tuberculosis vaccine candidate that could be the first in 100 years if proven effective. Seattle: Gates Foundation, 2023. https://www.gatesfoundation.org/ideas/media-center/press-releases/2023/06/ funding-commitment-m72-tb-vaccine-candidate (accessed 8 January 2024).
Lewnard JA, Lo NC, Arinaminpathy N, Frost I, Laxminarayan R. Childhood vaccines and antibiotic use in low- and middle-income countries. Nature 2020;581(7806):94-99. https://doi.org/10.1038/ s41586-020-2238-4
Kumar CK, Sands K, Walsh TR, et al. Global, regional, and national estimates of the impact of a maternal Klebsiella pneumoniae vaccine: A Bayesian modeling analysis. PLoS Med 2023;20(5):e1004239. https:// doi.org/10.1371/journal.pmed.1004239
Page N, Seheri L, Groome M, et al. Temporal association of rotavirus vaccination and genotype circulation in South Africa: Observations from 2002 to 2014. Vaccine 2018;36(47):7231-7237. https:// doi.org/10.1016/j.vaccine.2017.10.062
Lewnard JA, Fries LF, Cho I, Chen J, Laxminarayan R. Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus. Proc Nat Acad Sci 2022;119(12):e2112410119.
Knight GM, Clarkson M, de Silva TI. Potential impact of influenza vaccine roll-out on antibiotic use in Africa. J Antimicrob Chemother 2018;73(8):2197-2200. https://doi.org/10.1093/jac/dky172
National Department of Health, South Africa. South African Antimicrobial Resistance National Strategy Framework: A One Health Approach 2018 - 2024. Pretoria: NDoH, 2018. https://www. who.int/publications/m/item/south-africa-south-african-antimicrobial-resistance-national-strategy- framework-a-one-health-approach (accessed 8 January 2024).
Van Heuvel L, Paget J, Dückers M, Caini S. The impact of influenza and pneumococcal vaccination on antibiotic use: An updated systematic review and meta-analysis. Antimicrob Resistance Infect Control 2023;12(1):70. https://doi.org/10.1186/s13756-023-01272-6
Williams CT, Zaidi STR, Saini B, Castelino R. The role of adult vaccines as part of antimicrobial stewardship: A scoping review. Antibiotics 2023;12(9):1429. https://doi.org/10.3390/ antibiotics12091429
Van Werkhoven CH, Bolkenbaas M, Huijts SM, Verheij TJ, Bonten MJ. Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: Secondary analysis of a double-blind randomized placebo-controlled study. Clin Microbiol Infect 2021;27(7):995-999. https://doi.org/10.1016/j.cmi.2020.09.011
Downloads
Published
Issue
Section
License
Copyright (c) 2024 A Brink, A Kgasi, A Musyoki, B Kagina, C Feldman, D Reddy, E du Toit, E Kalanxhi, J Meyer, I Impalli , M Schönfeldt, M Sibanda, N Schellack, P Skosana , S Essack , S Dlamini, Y Ramsamy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.